Sugi Predict

Sugi Predict / Compounds / SCHEMBL3553535

SCHEMBL3553535

SCHEMBL3553535

CCOC(=O)C1(C(=O)Cl)CCC1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ POLB P06746 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ OPRM1 P35372 5/20 0.35
▸ LMNA P02545 2/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ OPRD1 P41143 2/20 0.34
▸ OPRK1 P41145 2/20 0.34
▸ ATM Q13315 1/20 0.34
▸ SLC22A1 O15245 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ ADRA1A P35348 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9416724 0.96 MEN1 (0.40) MEN1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL11725215 0.94 MEN1 (0.39) MEN1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL3552438 0.92 ALDH1A1 (0.39) MEN1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL713102 0.87 SMN1; SMN2 (0.46) MEN1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL1152835 0.83 SMN1; SMN2 (0.42) MEN1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL5787834 0.82 SMN1; SMN2 (0.42) MEN1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL1654017 0.82 SMN1; SMN2 (0.46) MEN1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL254353 0.81 SMN1; SMN2 (0.41) MEN1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL9806689 0.81 SMN1; SMN2 (0.41) MEN1KMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL4640203 0.80 ALOX15 (0.43) MEN1KMT2ASMN1; SMN2POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115515943-B Oxadiazole derivatives 住友制药株式会社 2024-07-09 — — CN disclosed
CN-115515943-A Oxadiazole derivatives 住友制药株式会社 2022-12-23 — — CN disclosed
EP-1889836-B1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) EISAI R&D MAN CO LTD (JP) 2013-06-12 — — EP disclosed
US-8288538-B2 Pyridine derivatives and pyrimidine derivatives (3) EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-10-16 — — US disclosed
US-20120232049-A1 PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-09-13 — — US disclosed
US-7855290-B2 N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-21 — — US disclosed
US-20100075944-A1 NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) MATSUSHIMA TOMOHIRO 2010-03-25 — — US disclosed
EP-2119706-A1 PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE Eisai R&D Management Co., Ltd. (JP) 2009-11-18 — — EP disclosed
US-20080319188-A1 Novel pyridine derivatives and pyrimidine derivatives (3) EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-12-25 — — US disclosed
EP-1889836-A1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) Eisai R&D Management Co., Ltd. (JP) 2008-02-20 — — EP disclosed
EP-1587783-A4 CYCLOALKYL CONTAINING ANILIDE LIGANDS FOR THE THYROID RECEPTOR BRISTOL MYERS SQUIBB CO (US) 2006-11-08 — — EP disclosed
EP-1587783-A2 CYCLOALKYL CONTAINING ANILIDE LIGANDS FOR THE THYROID RECEPTOR Bristol-Myers Squibb Company (US) 2005-10-26 — — EP disclosed
US-20040176425-A1 Cycloalkyl containing anilide ligands for the thyroid receptor BRISTOL-MYERS SQUIBB COMPANY 2004-09-09 — — US disclosed
WO-2004066929-A2 CYCLOALKYL CONTAINING ANILIDE LIGANDS FOR THE THYROID RECEPTOR BRISTOL-MYERS SQUIBB COMPANY (US) 2004-08-12 — — WO disclosed
US-5292937-A Use of malonic acid derivative compounds for retarding plant growth RHONE-POULENC INC. (US) 1994-03-08 — — US disclosed
US-5123951-A Ethylene response inducing agent and malonic acid derivative RHONE-POULENC NEDERLAND B.V. (NL) 1992-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232049-A1 PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE HGF, MET, MKI67 MEN1 2263/4885KMT2A 3405/4885SMN1; SMN2 4406/4885
US-20040176425-A1 Cycloalkyl containing anilide ligands for the thyroid receptor TSHR, THRB, TRHR MEN1 3912/4885KMT2A 3707/4885SMN1; SMN2 4835/4885
US-20080319188-A1 Novel pyridine derivatives and pyrimidine derivatives (3) HGF, MET, FLT4 MEN1 3561/4885KMT2A 4189/4885SMN1; SMN2 4771/4885
US-20100075944-A1 NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) HGF, MET, HDGF MEN1 3868/4885KMT2A 4123/4885SMN1; SMN2 4767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.